News

March 8, 2018

WuXi Biologics and Adagene Announce Strategic Development and Manufacturing Partnership of New Antibody Therapeutics

SHANGHAI¬† — WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Adagene Inc., an emerging biotech company discovering and developing innovative antibody therapeutics for the global market, today announced a strategic collaboration agreement.

Adagene is building a global biotech company with an internal pipeline of antibody therapeutics focused on difficult antigens, and therapeutic candidates with enhanced biophysical properties. The collaboration with WuXi Biologics will support supply of Adagene’s products for clinical trials under Investigational New Drug (IND) applications in both China and United States.

“The strategic collaboration with WuXi Biologics will enable Adagene to focus on our core competency in the discovery of novel antibody therapeutics and by leveraging the process development and manufacturing capabilities of WuXi Biologics will accelerate Adagene’s next wave of innovative products into the clinic,” said Dr. Peter Luo, Co-Founder and CEO of Adagene.

Read More

Back to News